Comparative Pharmacology of Plant-Derived and Synthetic Ellagic Acid Derivatives: Sources, Bioavailability, and Molecular Mechanisms in Dermatology

Ellagic acid (EA) is a polyphenolic molecule which appears in diverse plants, including not only berries and pomegranates, but also nuts and even hardwoods. Naturally it is largely confined within the ellagitannins, hydrolyzable tannins which dissociate, either chemically or enzymatically, to liberate EA (1, 2). Due to its reputed antioxidant, anti-inflammatory and chemopreventive effects, much work has been done on the potential benefits of EA in increasing health (3, 4, 5).

The first hiccup is that EA is polarized and is quickly metabolised and conjugated in the liver and stomach, hence not very water-soluble and poor oral bioavailability, which means it can only be used in practice with certain limitations, although it is biologically active (6, 7). Gut microbiota have the ability to convert EA and its ellagitannin precursors to urolithins. These analogs are more bioavailable and have a longer duration of action compared to the parent compound (8, 9). The microbial metabolism of Urolithin A in specific has been demonstrated to stimulate mammalian models and increase tissue activity, emphasizing the value of microbial metabolism in EA pharmacology (10).

All causes of skin damage include oxidative stress, inflammation and sun exposure (photoaging). It is essential to protect the cells against the UV light (11, 12). The mechanism of action of EA seems to be the activation of antioxidant response elements, the upregulation of genes that enhance antioxidant enzymes by HO-1 and NRF2 signalling and contribute to the reduction of the damaging oxidative stress of keratinocytes (12). Some of the other inflammatory mediators that are blocked by EA and its derivatives include NF-κB and MAPK/STAT pathways, which mediate skin inflammation and aging (13, 14).

As a result of these shortcomings, researchers have come up with formulations and various synthetic EA derivatives to improve its pharmacokinetics and therapeutic efficacy in dermatology. They are semi-synthetic analogs, nanoemulsion systems and other carrier mechanisms enhancing delivery, stability and sustained release of EA to the skin (15, 16, 17). To establish the structure-activity relationships, a comparative study of the effectiveness of these plant-based and synthetic EA variants will be used to obtain the desired clinically effective skin health results.

The purpose of this review is to combine the existing information about the sources, bioavailability, and molecular mechanisms of natural and synthetic derivatives of ellagic acid, in terms of their pharmacological meaning in the field of dermatology. Through the comparison of natural metabolites and their engineered analogs, we believe that we can have a better understanding of strategies to improve therapeutic benefits and also to lead us to future research in phytochemical based skin therapeutics.

2. CHEMICAL STRUCTURES AND SOURCES OF ELLAGIC ACID

Ellagic acid (EA) is a natural polyphenol that is mostly found in plant sources that contain ellagitannins. EA consists of a dimeric derivative of gallic acid with a molecular weight of 302.194 g/mol. Structurally, EA is a dilactone of hexahydroxydiphenic acid, consisting of a biphenyl core linked to two lactone rings and four hydroxyl groups (3). This unique arrangement allows EA to act as a potent antioxidant, as the hydroxyl groups can donate hydrogen atoms to neutralize free radicals, chelate metal ions, and inhibit oxidative damage (3,18). The planar biphenyl structure and the lactone moieties are critical for its interaction with biomolecules and its pharmacological activity (19). According to IUPAC nomenclature, EA is identified as 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione, though the most common designation in chemistry may be found based on diphenic acid classification (4,4′,5,5′,6,6′-hexahydroxydiphenic acid 2,6,2′,6′-dilactone). EA comprises four free OH groups and two acyloxy groups linked to a core of fused aromatic rings, keeping a near planar structure with molecular symmetry C_2h and crystallizing in the monoclinic cell, space group P2₁/c (26). EA dihydrate forms triclinic crystals representing characteristics of the P1 space group (27). The diverse EA crystal structures obtained in nature are attributed to the related compounds and subsequent metal complexes, which form different crystalline forms (28).

Ellagic acid is found in nature mostly in the form of ellagitannins, which are high-molecular-weight polyphenols. Through digestion or processing these tannins are broken down to give out free EA which in turn can have its biological effects (1). Some of the significant food sources of EA are fruits like pomegranate (Punica granatum), strawberries, raspberries and nuts like walnuts (4,9). EA is primarily complexed in ellagitannins in these foods which are metabolised by intestinal microbiota into urolithins, bioavailable and biologically active metabolites (8,9).

Synthetic and semi-synthetic EA derivatives have been designed to increase their solubility, stability and bioavailability to use in pharmacological and dermatological use (19,20). Such derivatives preserve the biphenyl-lactone framework of EA but enable these to be modified to enhance chemical stability, skin penetration or systemic absorption (15). The ease of chemical modification of EA and its subsequent maintenance of its antioxidant and anti-inflammatory activity makes it a ubiquitous candidate in dermatology, particularly in the prevention of oxidative stress, UV damage, and inflammation.

Overall, ellagic acid is a distinctive polyphenol that has a biphenyl -lactone structure and is abundantly found in plants under the form of ellagitannins and can be chemically substituted to enhance pharmacokinetics. Its presence both naturally occurring in fruits and nuts as well as in a synthetic form, highlights the significance of both a natural and engineered version of the compound, in terms of the therapeutic and cosmetic formulas (19).

3. TYPES OF ELLAGIC ACID DERIVATIVES

Ellagic acid (EA) exists in multiple forms depending on its origin and chemical modification. The derivatives can be broadly classified into plant-derived, semi-synthetic, and synthetic forms, each with unique chemical structures and functional applications, particularly in dermatology and pharmacology.

1. Plant-Derived Ellagic Acid and Its Derivatives

Plant-derived EA primarily occurs in ellagitannins, which are complex polyphenolic molecules containing EA moieties bound to sugar units. In nature, EA is rarely found in its free form instead, it exists as part of hydrolysable tannins, such as punicalagin, punicalin, and casuarictin, predominantly found in pomegranate, berries, and walnuts (1,2,9).

Chemical derivation:  Hydrolysis of ellagitannins (enzymatic or acidic) releases free EA:

• Ellagitannins (ETs): These are the most common natural derivatives. They are hydrolyzable tannins where EA is esterified to a sugar moiety (usually glucose). Examples include punicalagin and punicalin (pomegranate), agrimoniin (strawberry), and sanguin H-6 and lambertianine C (raspberry) (4).
• Ellagic Acid Glycosides: EA conjugated with sugar residues such as glucose, arabinose, xylose, or rhamnose, such as 3-O-β-D-glucopyranoside (9).
• Methylated/Methoxylated Ellagic Acids: Natural derivatives where hydroxyl groups are replaced by methoxy groups, increasing lipophilicity. Examples include 3-O-methylellagic acid and 3,3'-di-O-methylellagic acid.
• Sulfated Derivatives: Rare in nature, these include 3,3',4-trimethoxy-4'-sulphoxyellagic acid (found in Potentilla candicans), which shows high activity against aldose reductase.
• Urolithins (Microbial Metabolites): While not strictly "plant-derived," these are the in vivo metabolites produced by gut microbiota from ellagitannins, including urolithin A, B, C, and D (19, 29).

2. Semi-Synthetic Ellagic Acid Derivatives

Semi-synthetic derivatives are chemically modified forms of EA that are extracted from plants, which are designed to improve solubility, stability, or biological activity. These are commonly produced by esterification, alkylation, or complexation.

1. Esterification of hydroxyl groups:
   • Hydroxyl groups of EA react with fatty acids or alcohols to form lipophilic esters.
   • Example: 3-O-decyl EA – esterification of the C3 hydroxyl group with decyl alcohol improves topical absorption (21). Modification of the four phenolic hydroxyl groups (e.g., tetrabenzoyl ellagic acid) to increase hydrophobicity for better cellular uptake.

2. Hydrogen-bond complex formation:
   • EA can form non-covalent complexes with urea or cyclodextrins to enhance water solubility.
   • Example: EA–urea complex improves antioxidant activity and solubility for topical applications (20).
3. Lactone Ring-Opened Derivatives: Base hydrolysis of EA open its lactone rings, resulting in product like octasodium salt of hydrolysed Ellagic acid, which shows better solubility in specific environment. (30)                        
4. Alkylation and methylation:
   • Selective substitution of hydroxyl groups with alkyl or methyl groups reduces polarity and improves lipophilicity.
   • Example: 3,3’-di-O-methylellagic acid – hydroxyl groups methylated to allow incorporation into lipophilic dermal formulations (19).

hese derivatives generally exist as esters, salts, or hydrogen-bonded complexes, making them more suitable for topical and oral formulations.

Semi-synthetic derivatives maintain the core biphenyl-lactone structure, preserving antioxidant activity with increase in pharmacokinetic properties (19).

3. Synthetic Ellagic Acid Derivatives

Synthetic derivatives are fully chemically synthesized molecules designed to mimic EA or enhance its activity in conditions where natural extraction is limited. These derivatives often feature substitutions on hydroxyl groups, methylation, or conjugation with polymers to increase bioavailability and dermal penetration (19).

Examples of synthetic derivatives:

• Hexahydroxydiphenyl (HHDP) Derivatives: Synthesized biphenyl-6,6'-dicarboxylic acid derivatives (often with benzyl or alkyl groups) have been developed as potential anti-HIV agents and DNA gyrase inhibitors (31).
• Biomimetic Synthesis Products: Researchers use oxidative coupling of gallic acid esters (like methyl gallate) using oxidants such as ferric chloride or silver oxide to synthesize EA and its analogs in a controlled environment.

• Methylated/Acetylated analogs

1. 3,3’-di-O-methylellagic acid – methylation at hydroxyl positions to reduce polarity (21).
2. 3-O-decylellagic acid – alkylation to increase lipophilicity for dermal formulations.

These derivatives are typically aglycones with lipophilic modifications, which exist in solid crystals or soluble oil-compatible forms, depending on the substituents.

4. ROLE OF GUT MICROBIOTA AND UROLITHIN FORMATION

The ellagic acid (EA) and ellagitannins found in pomegranate, berries, and nuts do not have a high absorption in the upper gastrointestinal tract because the compounds are poorly water solubable and have a large molecular form. Consequently, a significant percentage of these substances enter the colon and are converted to smaller and more bioactive metabolites called urolithins by intestinal microbiota (1,9,33). Ellagitannins are initially digested to free ellagic acid in the colon, which is further fractionated by particular gut bacteria by a series of reactions involving the cleavage of lactone rings, decarboxylation, and dehydroxylation. These microbial activities result in the production of a variety of urolithin derivatives such as urolithin D, C, A and B, which vary in the patterns of hydroxylation and biological activity (8,9). The urolithins are highly bioavailable in comparison to their parent compound and can be detected at micromolar concentrations in plasma and urine after the consumption of the ellagitannin-rich foods (33,34).

The synthesis of urolithins amongst different people differs significantly since it is determined by the makeup and metabolic capacity of the gut microbiota. Individuals have been categorized into various types of urolithin metabolotypes primarily metabotype A (producing urolithin A), metabotype B (producing urolithin A, B, and isourolithin A), and metabotype 0 (non-producers) based on their capacity to generate certain particular metabolites (9,35). The variability has great effect on the pharmacological outcomes of the intake of ellagic acid because urolithins are considered to be the main bioactive metabolites that cause most of the systemic biological processes. As an example, urolithin A was found to stimulate mitochondrial activity and trigger mitophagy thus improving cellular energy metabolism and muscle activity (10, 38). On the same note other urolithins have been shown to have antioxidant, anti-inflammatory and anticancer effects, in part by regulating oxidative stress and apoptotic signaling pathways (8,36).

These microbial metabolites could be involved in the protective activity of the ellagitannin-rich foods toward the oxidative stress and inflammation in the skin tissues in dermatological conditions. It has been reported that urolithins can regulate cellular antioxidant defenses and mediate the inflammation and apoptosis-linked signaling pathways, which indicate their possible application in the prevention of aging and oxidative damage of the skin (33,35). Consequently, the response of the dietary rich of ellagic acid and the gut microbiota is a key determinant of the pharmacokinetic profiles and biological activity of ellagic acid analogs. These microbial transformations are needed to explain interindividual variations in therapeutic response and to develop strategies to enhance the bioavailability and dermatological advantages of ellagic acid-based compounds (34,37).

5. BIOAVAILABILITY AND PHARMACOKINETICS

Ellagic acid (EA) is a compound that has low oral bioavailability due to its low water solubility and low intestinal absorption. In the event of oral intake, EA is taken in by the stomach and the upper small intestine by means of passive diffusion. Research indicates that with a dietary source or hydrolyzed, ellagitannin concentration, free EA can achieve peak plasma concentrations ( Cmax ) of about 18-320 ng / mL (≈ 0.06-1.06 μM) and a Tmax of about 1 hour when ingested in a form of ellagitannin-rich products like pomegranate juice (4, 32,33). But it is only a minor percentage that gets into the systemic circulation because there is a great amount of first-pass metabolism in the intestinal wall and liver where EA is quickly changed into phase II conjugates such as glucuronides, sulfates, methyl esters, and dimethyl esters that are detectable in plasma and urine 1-5 hours after the intake (34). The compound is also characterized by a high plasma protein binding and low tissue accumulation as well as in certain animal experiments it becomes hard to find in plasma or liver, even in case of repeated dosing. A large part of the unabsorbed EA is excreted to the colon where it is biotransformed by gut microbiota to urolithins (A, B, C, and D). These metabolites are much more bioavailable with it being reported to be 25-80 times higher than the parent compound and possibly reaching plasma concentrations as high as approximately 18.6 μM. An individual ability to generate urolithins varies as a result of the gut microbial composition, giving rise to different metabotypes (A, B, and 0) (32). In general, EA shows a comparatively low elimination half-life (about 0.7 to 8.4 hours), which suggests a high metabolic clearance and minimal enterohepatic recidivation. The compound and its metabolites are excreted primarily in the form of conjugated metabolites into the urine and the unmetabolized EA or microbial derivatives in the feces where plasma concentrations typically fall to very low levels after consumption(17,32,33).

The bioavailability and pharmacokinetic properties of ellagic acid (EA) have a significant impact on the therapeutic efficacy of the substance in the dermatology field. Plant based EA, which is mostly found as ellagitannins, has low absorbency in the small intestine because it has a high molecular weight and is polar. Nevertheless, intestinal microbiota convert ellagitannins to bioactive urolithin A and C (urolithins), which have enhanced systemic absorption and of bioactivity (8,10). These metabolites of microbial origin are associated with antioxidant, anti-inflammatory, and anti-melanogenic action in the skin, and due to inter-individual differences in the composition of microbial fauna, there is a possibility of variability in bioavailability (9).

To address the natural weaknesses of natural EA like insufficient solubility and penetration through the skin, semi-synthetic derivatives of EA have been discovered. Lipophilicity is increased by chemical modifications, such as esterification, methylation, and the creation of the urea complexes, which increases dermal absorption (20,21). As an example, lipophilic esters of EA, including 3-O-decyl EA, are more readily penetrate skin via stratum corneum, and methylated esters are more stable in topical formulations. Aqueous solubility is further enhanced due to the use of urea complexes, which can ultimately be incorporated into gels, creams or emulsions. Such changes allow semi-synthetic EA derivatives to build up domestically in the keratinocytes and dermal fibroblasts in which they retain their antioxidant and anti-inflammatory potential. Synthetic EA derivatives are optimally bioavailable and predictable to pharmacokinetics. Nanoemulsion, liposomal formulation, and phospholipid conjugation are the approaches that help protect EA against quick degradation and increase the dermal delivery (19,22).

That way we can conclude that plant-based EA involves the use of gut microbes to synthesize the active metabolites, semi-synthetic derivatives optimize the solubility and skin penetration to enhance bioavailability and completely synthetic derivative operate on sophisticated delivery systems to achieve predictable pharmacokinetics. These strategies are all in concert to ensure that EA has the best therapeutic potential in dermatology since it leads to the proper delivery of EA, stable formulations, and high bioactivity immediately to the target areas of the skin.

6. MOLECULAR MECHANISMS AND PHARMACODYNAMICS

Ellagic acid (EA) and its analogues show various pharmacodynamic activities pertinent to skin health such as antioxidant, anti-inflammatory, anti-melanogenic, and photoprotective activity. These processes play a critical role in the prevention or mitigation of skin damage due to oxidative stress, UV radiation and inflammatory mediators. The difference in bioavailability, chemical modification, and delivery among the derivatives (plant-derived, semi-synthetic, and synthetic) contributes to the difference in the pharmacodynamic profile.

Pomegranates, berries, and other plants with abundant polyphenols produce natural ellagitannins which can be mainly via the microbial metabolites, urolithins, generated by the gut microbes. These metabolites have high antioxidant capabilities by seeking reactive oxygen species (ROS) and stimulating innate antioxidant pathways (8,10). Moreover, EA of plant origin inhibits pro-inflammatory signaling, inhibiting the activation of NF-κB and the cytokine expression of TNF-α, IL-6 and COX-2 in keratinocytes and fibroblasts (5). EA reduces melanin production and has anti-hyperpigmentation effects by reducing the activity of tyrosinase in melanocytes (26). The variable gut metabolism and low systemic absorption is one of the limitations that impairs the efficacy of the topical application unless it is formulated. Another important pharmacodynamic action is anti-melanogenic activity, which is applicable to pigmentation disorders; EA-saturated agents suppress melanogenesis by suppressing the microphthalmia-associated transcription factor (MITF) and its melanin-producing enzymes (23). Nanoformulations and synthetic EA derivatives also stimulate delivery to melanocytes and provide effective depigmenting effects in topical application (22).

A semi-synthetic derivative, e.g. lipophilic esters or urea complexes, is designed to enhance solubility, stability and skin penetration (20,21). These alterations allow direct local pharmacodynamic action without the assistance of metabolism in the microbes. Semi-synthetic EA preserves the antioxidant properties by inhibiting ROS and lipid peroxidation in the keratinocytes and may regulate the MAPK and STAT signaling pathways to prevent inflammation (13). Semi-synthetic derivatives offer superior pharmacodynamic properties to plant-derived EA due to their superior stability and dermal bioavailability, thus making them the best in topical anti-aging, anti-inflammatory, and UV-protective preparations.

Synthetic EA derivatives are fully synthetic, and usually presented in the form of nanoemulsions, liposomes, or phospholipid conjugates, so as to maximize pharmacodynamic and pharmacokinetic efficacy (19,22). These derivatives exhibit predictable tissue distribution, high local epidermis and dermis tissue concentrations and long activity. Synthetic EA exhibits excellent ROS scavenging, inhibits UV-induced inflammatory mediators and melanogenesis in pharmacodynamics. Nano-formulated EA also lessens enzymatic degradation, improves anti-inflammatory and photoprotective effects in the long term than both the plant-derived forms and semi-synthetic analogs. The predictable treatment results due to this controlled delivery in dermatology, especially with chronic inflammatory or photoaging diseases, make it reliable (25).

In addition, EA stimulates cellular antioxidant defense mechanisms through the stimulation of the Nrf2/ARE signaling pathway, which increases the expression of anti-oxidant enzymes, including heme oxygenase -1 (HO -1). This does not only contribute to the ROS scavenging but also prevents the UV-induced damage and inflammation (24). Evidence of the direct pharmacodynamic impact of EA on the molecular mechanism is the activation of Nrf2 which prepares skin cells to oxidative and inflammatory stressors.

1. ROS Scavenging (Antioxidant Activity)

Reactive oxygen species (ROS) are highly reactive molecules generated in the skin due to UV exposure, pollution, or metabolic stress. EA is a potent antioxidant and this is because it directly scavenges ROS such as superoxide anions, hydroxyl radicals, and hydrogen peroxide (8). This is useful in reducing oxidative stress on lipids, proteins and DNA in keratinocytes and fibroblasts, in effect inhibiting photoaging and cellular senescence. As neutralizers of such free radicals, EA keeps cellular redox balance within check which is important in ensuring that the skin is healthy and the rocks along the process of repair.

2. Modulation of MAPK/STAT Signaling pathway

EA alters the essential signaling cascades in the cell, and in particular, the Mitogen-Activated Protein Kinase (MAPK) and Signal Transducer and Activator of Transcription (STAT) pathways. These signaling pathways process the inflammation, cell growth and stress reactions in the skin. EA prevents the phosphorylation of the MAPKs such as p38, ERK, and JNK hence, it drags down the expression of the pro-inflammatory genes and matrix metalloproteinases (MMPs) that break down collagen (13). Similarly, EA inhibits the transcription of STAT3, reducing the production of inflammatory cytokines and increasing cell survival under oxidative stress conditions. All these mechanisms result in EA keeping the UV-induced inflammation and photoaging under control.

3. Suppresion of Pro-inflammatory

EA fundamentally disrupts the production and action of cytokines including TNF- α, IL-6 and COX-2, mediators of skin inflammation (5). Inhibiting these mediators, EA reduces inflammatory reactions in keratinocytes and dermal fibroblasts and serves to reduce erythema, edema, and tissue damage associated with UV exposure or inflammatory skin diseases. This effect as an inhibitor of NF-κB, a transcription factor that regulates the expression of cytokine genes, contributes to this anti-inflammatory activity.

4. Inhibition of Melanogenesis

EA will reverse the process of hyperpigmentation by interfering with melanogenic enzymes. Essentially, it prevents tyrosinase that is important in the formation of melanin and also reduces the level of MITF- the person who activates the tyrosinase and other enzymes (23.25). Thus, reducing melanin, EA can prevent UV-browning and sunspots, which is convenient to use as a sunscreen and skin-lightener.

5. Activation of Nrf 2- Mediated Antioxidant Pathway

Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway which is a master regulator of antioxidant defense in the cell is also activated by EA (24). Upon activation, Nrf2 leaps into the nucleus and increases the expression of cytoprotective enzymes, such as heme oxygenase 1 (HO -1 ), superoxide dismutase (SOD), and glutathione peroxidase (GPx). This enhances our innate immune system, reduces oxidative injury, and assists in maintaining skin homostasis during environmental or chemical pressures.

7. DERMATOLOGICAL PHARMACOLOGY OF ELLAGIC ACID

Ellagic acid (EA) and its derivatives exhibit a broad spectrum of pharmacological actions in dermatology, including antioxidant, anti-inflammatory, anti-melanogenic, photoprotective, and wound-healing effects. The efficacy of EA in skin applications depends not only on its molecular activity but also on its derivative type, formulation, and percutaneous absorption, which influences its local bioavailability and pharmacological outcome.

1. Antioxidant Pathways (Nrf2/HO-1)

Oxidative stress is a giant of all kinds of skin issues, including that of photoaging, uneven pigmentation and the irritating inflammatory skin diseases. Ellagic acid (EA) is one of the compounds that are useful in protecting the skin; it acts as a powerful antioxidant. At the molecular process, EA triggers the Nrf2 signaling mechanism, the nuclear factor erythroid-2 related factor 2. Nrf2 regulates the expression of a number of cytoprotective enzymes. Upon activation, Nrf2 translocates into the nucleus and then induces the expression of antioxidant response factors such as heme oxygenase -1 (HO-1), superoxide dismutase, and catalase. This process enhances self-protective mechanism of the skin against oxidative stress of UV radiation and environmental pollution. Regulating such antioxidant pathways, EA decreases the levels of reactive oxygen species (ROS) within cells and contributes to the redox balance in keratinocytes and melanocytes (5,8).

2. Anti-melanogenic Activity

Excessive melanin levels and disrupted melanogenic signaling pathways are normally the cause of hypertrophic pigmentation disorders. According to my notes in the classroom, ellagic acid has the potential to indeed reduce melanin production in a number of ways. The former is the inhibition of tyrosinase, the enzyme that converts tyrosine into the melanin building blocks. In addition, ellagic acid interferes with the microphthalmia-associated transcription factor (MITF), which takes the centre stage in ensuring the sprouting of melanocytes and their synthesis of melanin. According to some recent research, it is also possible that ellagic acid can cause autophagy in melanocytes, which breaks melanosomes and makes the skin lighter. To add to that, it advances the a-melanocyte-stimulating hormone signaling, which is flipped on by UV light, hence the skin is not over-stimulated to generate more melanin (8).

3. Anti-inflammatory Signaling

Inflammation is another major contributor in aging the skin and a number of skin conditions. Ellagic acid has the ability to cool the inflammation by messing with a plethora of cell signaling pathways, which suppresse an immune response. Research indicates that EA suppress the nuclear factor-κB (NF- κB) which is a major transcription factor that regulates much of inflammatory signatures such as TNF- α, IL- 6 and COX- 2. In addition, EA disrupts the MAPK and STAT pathways that play a significant role in inflammatory signaling and cellular response to stress. EA reduces the production of cytokines and minimizes the inflammatory injury of skin tissues by inhibiting these pathways (5,13).

4. Photoprotection

Ellagic acid completely assists in preventing UV damage to the skin. Exposure by UVA and UVB, they generate reactive oxygen species that destroy cellular macromolecules such as DNA, proteins, even fats that line our cell walls. In essence, EA suppressed the activity of those free radicals, alleviating the oxidative stress in the keratinocytes as well as in the dermal fibroblasts (8). Ellagic acid reduces the activation of those MAPK and STAT signaling pathways triggered by UV and reduces the number of pro-inflammatory cytokines which typically induce redness, swelling and that early photoaging (5,13). More recently, scientists have been fiddling with semi-synthetic forms of EA derivatives and nano-delivery vehicles to ensure it adheres to the skin and remains stable, which in fact increases its sunprotective properties when put on the skin (19,22).

8. FORMULATION STRATEGIES TO IMPROVE BIOAVAILABILITY

Ellagic acid has a low systemic bioavailability due to its minimal systemic bioavailability caused by its low aqueous solubility, low intestinal permeability and extensive first-pass metabolism, and limited bioavailability after oral administration. Due to such pharmacokinetic difficulties, scientists have developed a number of formulation theories, to enhance its solubility, stability, absorption, and overall biological effectiveness. Nanotechnology-based delivery systems, the formation of complexes, and structural modification of ellagic acid are the primary subjects of modern pharmaceutical approaches to enhance the pharmacokinetic profile and therapeutic performance of ellagic acid (6,17).

The utilization of nanocarrier systems, including nanoemulsions, liposomes, polymeric nanoparticles, and solid lipid nanoparticles, is one of the most studied methodologies. These nanocrystallized networks are able to increase the rate of dissolution of soluble compounds and the absorption by biological membranes. As an example, nanoemulsion-based preparations of ellagic acid have demonstrated superior stability, enhanced skin penetration and antioxidant and anti-aging effects in cosmetic and dermatological use (22). The use of nanoparticle-based delivery systems could also prevent the early degradation and enzymatic metabolism of ellagic acid in the gastrointestinal system and enhance its bioavailability and therapeutic efficacy (17).

The other significant approach is the development of inclusion complexes or molecular complexes with carrier molecules which increase the solubility of ellagic acid. Its solubility in aqueous solution and antioxidant properties have been shown to be enhanced significantly by complexation with such substances as urea or cyclodextrins. As an illustration, the ellagic acid-urea complex demonstrated enhanced solubility and radical scavenging activity compared to the free one, which suggests that such complexes could be used in pharmaceutical and cosmetic preparations (20). These complexes augment the new rise in the dispersion of the molecules and decrease the crystallinity of ellagic acid and hence increases the efficacy of its dissolution and absorption.

Another possible way to overcome the physicochemical limitations of ellagic acid is the chemical modification and synthesis of semisynthetic or fully synthetic analogs. Structural modification has the potential to increase lipophilicity, membrane permeability, and metabolic stability without altering or reducing biological activity. A number of newly synthesized ellagic acid analogs have been found using computational and experimental properties to be better drug-like in nature, and rational chemical modification has been shown to produce compounds with improved pharmacokinetic properties (30,31). Also, naturally derived derivatives that have been found in different plants have been shown to have better antioxidant and pharmacological functionality as compared to the parent compound (29).

Topical dermatological formulations are also being considered in encapsulation methods that include polymeric matrices, hydrogels and lipid-based carriers. These systems stabilize ellagic acid, offer controlled release, and enhance penetration across the skin barrier. These delivery systems are very advantageous especially in the dermatology field where sustained release and enhanced dermal uptake is vital in attaining therapeutic outcomes against conditions such as hyperpigmentation, inflammation, and photoaging (15).

In general, the formulation strategies to avert the pharmacokinetic restrictions of ellagic acid have been developed to achieve the objectives. Nanotechnology-derived delivery systems, complex formation strategy, and structural modification strategies have proved to be promising in improving solubility, stability and absorption. These techniques do not only enhance the bioavailability of ellagic acid, but also expand its possible use in the dermatology and in other therapeutic areas (6, 16, 17).

9. RESEARCH GAP/ FUTURE SCOPE

Although there are much more positive changes in determining the pharmacological potential of ellagic acid (EA) and its derivatives, we cannot omit several important gaps in the research. The absence of long-term clinical trials assessing the dermatological efficacy and safety of EA and its derivatives in actual human groups can be listed among the greatest limitations in the existing literature. We have mostly known the evidence in vitro experiments, animal model or brief clinical studies and it is difficult to determine the appropriate therapeutic dosage, long-term safety and long-term skin benefits. The potential of EA-based formulations in the translationation of skin ailments would most certainly be proven with larger cohorts and longer follow-up time in future clinical trials.

The other significant gap in research is the metabolism of ellagic acid to urolithins. It is not a secret that EA undergoes gut microbiota bio-transformation into bioactive urolithins that are more bioavailable and possess a variety of biological activities. But that remains unknown, whether a similar metabolic process occurs in the microenvironment of the skin or during interactions with the microbiome of the skin. So far, there is no conclusive dermatological research that deals with whether EA can transform to urolithin metabolites in the cutaneous tissues or whether the latter protect the skin. The research on the relationship between EA and the skin microbiome, as well as local metabolic pathways, may thus be a major future research focus in dermatology.

Lastly, native EA has a low bioavailability also presents a challenge to its therapeutical application. Whereas nanocarriers, nanoemulsions, and semisynthetic derivatives have already demonstrated potential in enhancing stability, permeability and controlled delivery, we have yet to refine these systems further, in order to enhance them in the context of clinical dermatology. Comparative research carried out on plant-derived versus synthetic analogs concerning pharmacokinetics, skin penetration, and biological activity would provide a worthwhile contribution to the development of more effective treatments in the dermatology field.

RESULT/CONCLUSION

Therefore, in essence, Ellagic acid (EA) is proving to be a very convenient multifunctional polyphenol in dermatology practice. A host of laboratory research and even an actual clinical trial demonstrates that EA has a formidable antioxidant, inflammatory soothing effect, ability to deal with the excessive melanin production, and shield against UV damage in the skin, which would be of immense help to our skin health. These cool effects predominately occur by activating the Nrf2/HO -antioxidant response, suppressing the inflammatory responses such as NF-κB and MAPK and manipulating the expression of melanin through regulation of tyrosinase and MITF. Generally, these processes assist in protecting the skin cells against oxidative stress, UV-related damage, and abnormal pigmentation.

The thing is, though, that the larger-scale application of EA in treatment remains somewhat unresearched due to its lack of solubility in water, the inability to effectively enter into the bloodstream, and degradation when in your gut. The gut bacteria are able to convert it into urolithins which enhance its bioactive profile, however, individual gut microbe compositions are different and thus the outcome may be different as well. In order to overcome these obstacles, scientists have been jiggering with recipes and chemical modifications to make the substance more resistant, much more soluble, and more skin- permeable.

In general, the comparison of plant-derived EA and its derivatives demonstrates the potential of the skin treatment in the future. Much of the analysis and investigation remains, of course, particularly exploring the processes behind such effects and conducting more clinical experiments, to ensure we really can put these into successful treatment.

11. ACKNOWLEDGEMENTS

The author thanks the department of pharmacy for academic support.

12. CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

1. 1. 1. Landete JM. Ellagitannins, ellagic acid and derived metabolites: A review. Food Research International. 2011;44(5):1150–1160.
      2. Cerdá B, Espín JC, Parra S, Martínez P, Tomás-Barberán FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable derivatives. European Journal of Nutrition. 2004;43(4):205–220. https://doi.org/10.1007/s00394-004-0461-7
      3. Priyanka C, Pandey A. Synergistic antioxidant activity of lipoic, ferulic and ellagic acid. International Journal of Pharmaceutical Sciences and Research. 2015;6(6):2551–2556. https://doi.org/10.13040/IJPSR.0975-8232.6(6).2551-56
      4. Seeram NP. Berry fruits for cancer prevention: Current status and future prospects. Journal of Agricultural and Food Chemistry. 2008;56(3):630–635. https://doi.org/10.1021/jf072504n
      5. Umesalma S, Sudhandiran G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-κB, iNOS, COX-2, TNF-α, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic and Clinical Pharmacology and Toxicology. 2010;107(2):650–655. https://doi.org/10.1111/j.1742-7843.2010.00565.x
      6. Zuccari G, et al. Formulation strategies to improve oral bioavailability of ellagic acid. Applied Sciences. 2020;10(10):3353. https://doi.org/10.3390/app10103353
      7. Kyriakoudi A, Kalfa E, Zymvrakaki E, Kalogiouri N, Mourtzinos I. Recovery of ellagic acid from pomegranate peels with the aid of ultrasound-assisted alkaline hydrolysis. Molecules. 2024;29(11):2424. https://doi.org/10.3390/molecules29112424
      8. Bialonska D, Kasimsetty SG, Khan SI, Ferreira D. Urolithins, intestinal microbial metabolites of pomegranate ellagitannins, exhibit potent antioxidant activity in a cell-based assay. Journal of Agricultural and Food Chemistry. 2009;57(21):10181–10186.
      9. Espín JC, Larrosa M, García-Conesa MT, Tomás-Barberán F. Biological significance of urolithins, the gut microbial ellagic acid-derived metabolites: the evidence so far. Evidence-Based Complementary and Alternative Medicine. 2013;2013:270418. https://doi.org/10.1155/2013/270418
      10. Ryu D, Mouchiroud L, Andreux P, et al. Urolithin A induces mitophagy and prolongs lifespan in C elegans and increases muscle function in rodents. Nature Medicine. 2016;22:879–888. https://doi.org/10.1038/nm.4132
      11. Bae JY, Choi JS, Kang SW, Lee YJ, Park J, Kang YH. Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Experimental Dermatology. 2010;19(8):e182–e190. https://doi.org/10.1111/j.1600-0625.2009.01044.x
      12. Hseu YC, et al. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food and Chemical Toxicology. 2012;50(5):1245–1255.
      13. Gil TY, Hong CH, An HJ. Anti-inflammatory effects of ellagic acid on keratinocytes via MAPK and STAT pathways. International Journal of Molecular Sciences. 2021;22(3):1277.
      14. Paruvu Y, Reddemma B, Vangalapati M. A comprehensive review on pharmacological activities of ellagic acid and its applications. Nanoparticle. 2025;6(1):18. https://doi.org/10.35702/nano.10018
      15. Castellacci R, Bergonzi MC. An insight on ellagic acid formulations for the management of skin diseases. Molecules. 2025;30(23):4493. https://doi.org/10.3390/molecules30234493
      16. Golmei P, Kasna S, Roy KP, Kumar S. A review on pharmacological advancement of ellagic acid. Journal of Pharmacology and Pharmacotherapeutics. 2024;15(2):93–104. https://doi.org/10.1177/0976500X241240634
      17. Ceci C, Graziani G, Faraoni I, Cacciotti I. Strategies to improve ellagic acid bioavailability: From natural or semisynthetic derivatives to nanotechnological approaches based on innovative carriers. Nanotechnology. 2020;31(38):382001. https://doi.org/10.1088/1361-6528/ab912c
      18. Ríos JL, Giner RM, Marín M, Recio MC. A pharmacological update of ellagic acid. Planta Medica. 2018;84(15):1068–1093. https://doi.org/10.1055/a-0633-9492
      19. Evtyugin DD, Magina S, Evtuguin DV. Recent advances in the production and applications of ellagic acid and its derivatives: A review. Molecules. 2020;25(12):2745. https://doi.org/10.3390/molecules25122745
      20. Sakurai H, Suzuki M, Itakura S, Todo H, Arce F Jr, See GL, Tanikawa T, Inoue Y. Preparation, characterization, solubility, and antioxidant capacity of ellagic acid–urea complex. Materials. 2022;15:2836. https://doi.org/10.3390/ma15082836
      21. Smart RC, Huang MT, Chang RL, Sayer JM, Jerina DM, Conney AH. Disposition of the naturally occurring antimutagenic plant phenol, ellagic acid, and its synthetic derivatives in mice. Carcinogenesis. 1986;7(10):1663–1667. https://doi.org/10.1093/carcin/7.10.1663
      22. Zhang H, et al. Ellagic acid nanoemulsion in cosmetics: The preparation and evaluation of a new nanoemulsion method as a whitening and antiaging agent. IEEE Nanotechnology Magazine. 2018;12(1):14–20. https://doi.org/10.1109/MNANO.2017.2780859
      23. Shu P, Xu N, Abudukelimu N, Aiziti P, Zang D, Zhao J, Wang Y. The pomegranate flower water extract negatively regulates melanogenesis by suppressing MITF expression and its target enzymes. Journal of Cosmetic Dermatology. 2025;24(4):e70163. https://doi.org/10.1111/jocd.70163
      24. Chaiprasongsuk A, Panich U. Role of phytochemicals in skin photoprotection via regulation of Nrf2. Frontiers in Pharmacology. 2022;13:823881. https://doi.org/10.3389/fphar.2022.823881
      25. Yoshimura M, Watanabe Y, Kasai K, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and ultraviolet-induced pigmentation. Bioscience, Biotechnology, and Biochemistry. 2005;69(12):2368–2373. https://doi.org/10.1271/bbb.69.2368
      26. Mathieson AM, Poppleton BJ. The crystal structure of ellagic acid. Acta Crystallographica Section B Structural Crystallography and Crystal Chemistry. 1968;24:1456–1461. https://doi.org/10.1107/S0567740868004474
      27. Rossi M, Erlebacher J, Zacharias DE, Carrell HL, Iannucci B. The crystal and molecular structure of ellagic acid dihydrate: A dietary anti-cancer agent. Carcinogenesis. 1991;12(12):2227–2232. https://doi.org/10.1093/carcin/12.12.2227
      28. Goriparti S, Harish MNK, Sampath S. Ellagic acid—a novel organic electrode material for high capacity lithium ion batteries. Chemical Communications. 2013;49:7234–7236. https://doi.org/10.1039/c3cc43194k
      29. Nuncio-Jáuregui N, Nowicka P, Munera-Picazo S, Hernández F, Carbonell-Barrachina ÁA, Wojdy?o A. Identification and quantification of major derivatives of ellagic acid and antioxidant properties of thinning and ripe Spanish pomegranates. Journal of Functional Foods. 2015;12:354–364. https://doi.org/10.1016/j.jff.2014.11.007
      30. Kamath C, Salvi S. Preparation of two new derivatives of ellagic acid and in-silico studies of their drug like properties. International Journal of Pharmaceutical Sciences and Research. 2025;16(8):2332–2347. https://doi.org/10.13040/IJPSR.0975-8232.16(8).2332-47
      31. Jadhav PD, Laddha KS. Synthesis of new ellagic acid derivatives. Indian Journal of Chemistry Section B. 2006;45B:1551–1553.
      32. Lin IC, Wu JY, Fang CY, Wang SC, Liu YW, Ho ST. Absorption and metabolism of urolithin A and ellagic acid in mice and their cytotoxicity in human colorectal cancer cells. Evidence-Based Complementary and Alternative Medicine. 2023;2023:8264716. https://doi.org/10.1155/2023/8264716
      33. Kang I, Buckner T, Shay NF, Gu L, Chung S. Improvements in metabolic health with consumption of ellagic acid and subsequent conversion into urolithins: Evidence and mechanisms. Advances in Nutrition. 2016;7(5):961–972. https://doi.org/10.3945/an.116.012575
      34. González-Sarrías A, García-Villalba R, Núñez-Sánchez MÁ, Tomé-Carneiro J, Zafrilla P, Mulero J, Tomás-Barberán FA, Espín JC. Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic study in healthy volunteers after consumption of pomegranate extracts. Journal of Functional Foods. 2015;19:225–235. https://doi.org/10.1016/j.jff.2015.09.019
      35. Leng P, Wang Y, Xie M. Ellagic acid and gut microbiota: Interactions, and implications for health. Food Science and Nutrition. 2025;13(4):e70133. https://doi.org/10.1002/fsn3.70133
      36. Yin P, Zhang J, Yan L, Yang L, Sun L, Shi L, Ma C, Liu Y. Urolithin C, a gut metabolite of ellagic acid, induces apoptosis in PC12 cells through a mitochondria-mediated pathway. RSC Advances. 2017;7(28):17254–17263. https://doi.org/10.1039/C7RA01548H
      37. Raya-Morquecho EM, et al. Ellagitannins and their derivatives: A review on the metabolization, absorption, and benefits related to intestinal health. Microbiology Research. 2025;16(6):113. https://doi.org/10.3390/microbiolres16060113
      38. Liu S, D’Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. JAMA Network Open. 2022;5(1):e2144279. https://doi.org/10.1001/jamanetworkopen.2021.44279